Oral absorption of poorly water-soluble drugs: Computer simulation of fraction absorbed in humans from a miniscale dissolution test

Pharmaceutical Research

Volumn 23, Issue 6, 2006, Pages 1144-1156

  Takano, Ryusuke ^a   Sugano, Kiyohiko ^a,c   Higashida, Atsuko ^a   Hayashi, Yoshiki ^a   Machida, Minoru ^a   Aso, Yoshinori ^a   Yamashita, Shinji ^b  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b SETSUNAN UNIVERSITY   (Japan)

^c Global Research and Development   (Japan)

Author keywords

Computer simulation; Dissolution; In vitro in vivo correlation; Oral absorption; Poorly water soluble

Indexed keywords

BONZOL; BUFFER; DANAZOL; DIPYRIDAMOLE; EFAVIRENZ; EXEMESTANE; GEFITINIB; GRISEOFULVIN; GUSERVIN FP; IVERMECTIN; KETOCONAZOLE; KETOPROFEN; NITRENDIPINE; PHENYTOIN; SPIRONOLACTONE; SULFANILAMIDE; WATER;

AREA UNDER THE CURVE; ARTICLE; COMPUTER SIMULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTESTINE MUCOSA PERMEABILITY; MATHEMATICAL MODEL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; THEORETICAL MODEL;

ABSORPTION; ADMINISTRATION, ORAL; BENZOXAZINES; BIOPHARMACEUTICS; CACO-2 CELLS; COMPUTER SIMULATION; GRISEOFULVIN; HUMANS; INTESTINAL ABSORPTION; IVERMECTIN; KINETICS; MODELS, BIOLOGICAL; OXAZINES; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; WATER;

EID: 33745416604     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-0162-4     Document Type: Article

References (51)

1. C. A. Lipinski 2000 Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 44 235 249
2. J. B. Dressman G. L. Amidon D. Fleisher 1985 Absorption potential: estimating the fraction absorbed for orally administered compounds J. Pharm. Sci. 74 588 589
3. R. J. Hintz K. C. Johnson 1989 The effect of particle size distribution on dissolution rate and oral absorption Int. J. Pharm. 51 9 17
4. L. X. Yu 1999 An integrated model for determining causes of poor oral drug absorption Pharm. Res. 16 1883 1887
5. J. B. Dressman D. Fleisher 1986 Mixing-tank model for predicting dissolution rate control or oral absorption J. Pharm. Sci. 75 109 116
6. A. A. Noyes W. R. Whitney 1987 The rate of solution of solid substances in their own solutions J. Am. Chem. Soc. 19 930 934
7. K. Obata K. Sugano R. Saitoh A. Higashida Y. Nabuchi M. Machida Y. Aso 2005 Prediction of oral drug absorption in humans by theoretical passive absorption model Int. J. Pharm. 293 183 192
8. H. Lennernas 1998 Human intestinal permeability J. Pharm. Sci. 87 403 410
9. J. C. [tmp] McGowan 1978 Estimates of the Properties of Liquids J. Appl. Chem. Biotechnol. 28 599 607
10. U. Fagerholm L. Borgstrom O. Ahrenstedt H. Lennernas 1995 The lack of effect of induced net fluid absorption on the in vivo permeability of terbutaline in the human jejunum J. Drug Target. 3 191 200
11. R. H. Perry D. W. Green 1999 Perry's Chemical Engineers' Platinum Edition McGraw-Hill New York
12. J. B. Dressman 1986 Comparison of canine and human gastrointestinal physiology Pharm. Res. 3 123 131
13. R. Lobenberg G. L. Amidon 2000 Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards Eur. J. Pharm. Biopharm. 50 3 12
14. J. B. Dressman C. Reppas 2000 In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs Eur. J. Pharm. Sci. 11 2 S73 S80
15. T. D. Bjornsson C. Mahony 1983 Clinical pharmacokinetics of dipyridamole Thromb. Res. Suppl. 4 93 104
16. B. Davies T. Morris 1993 Physiological parameters in laboratory animals and humans Pharm. Res. 10 1093 1095
17. O. Fausa 1974 Duodenal bile acids after a test meal Scand. J. Gastroenterol. 9 567 570
18. A. Tangerman A. van Schaik E. W. van der Hoek 1986 Analysis of conjugated and unconjugated bile acids in serum and jejunal fluid of normal subjects Clin. Chim. Acta. 159 123 132
19. L. J. Naylor V. Bakatselou N. Rodriguez-Hornedo N. D. Weiner J. B. Dressman 1995 Dissolution of steroids in bile salt solutions is modified by the presence of lecithin Eur. J. Pharm. Biopharm. 41 346 353
20. T. L. Russell R. R. Berardi J. L. Barnett T. L. O'Sullivan J. G. Wagner J. B. Dressman 1994 pH-related changes in the absorption of dipyridamole in the elderly Pharm. Res. 11 136 143
21. R. A. Blum D. T. D'Andrea B. M. Florentino J. H. Wilton D. M. Hilligoss M. J. Gardner E. B. Henry H. Goldstein J. J. Schentag 1991 Increased gastric pH and the bioavailability of fluconazole and ketoconazole Ann. Intern. Med. 114 755 757
22. Y. C. Huang J. L. Colaizzi R. H. Bierman R. Woestenborghs J. Heykants 1986 Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers Antimicrob. Agents Chemother. 30 206 210
23. L. A. Radesca, M. B. Maurin, S. R. Rabel, and J. R. Moore. Crystalline efavirenz. PCT Patent WO 99 64405 A1 (1999).
24. G. J. Peter, G. A. Stephen, Y. B. Ingvar, and B. Martin. Novel crystalline forms of the anti-cancer compound ZD1839. PCT Patent WO 03 072108 A1 (2003).
25. E. Galia E. Nicolaides D. Horter R. Lobenberg C. Reppas J. B. Dressman 1998 Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs Pharm. Res. 15 698 705
26. B. J. Aungst N. H. Nguyen J. P. Bulgarelli K. Oates-Lenz 2000 The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds Pharm. Res. 17 1175 1180
27. N. Parrot T. Lave 2002 Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA Eur. J. Pharm. Sci. 17 51 61
28. E. Nicolaides M. Symillides J. B. Dressman C. Reppas 2001 Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration Pharm. Res. 18 380 388
29. E. Nicolaides E. Galia C. Efthymiopoulos J. B. Dressman C. Reppas 1999 Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data Pharm. Res. 16 1876 1882
30. V. J. Stella S. Martodihardjo V. M. Rao 1999 Aqueous solubility and dissolution rate does not adequately predict in vivo performance: a probe utilizing some N-acyloxymethyl phenytoin prodrugs J. Pharm. Sci. 88 775 779
31. V. H. Sunesen B. L. Pedersen H. G. Kristensen A. Mullertz 2005 In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media Eur. J. Pharm. Sci. 24 305 313
32. R. J. Braun E. L. Parrott 1972 Influence of viscosity and solubilization on dissolution rate J. Pharm. Sci. 61 175 178
33. J. R. Crison V. P. Shah J. P. Skelly G. L. Amidon 1996 Drug dissolution into micellar solutions: development of a convective diffusion model and comparison to the film equilibrium model with application to surfactant-facilitated dissolution of carbamazepine J. Pharm. Sci. 85 1005 1011
34. S. Yamashita T. Furubayashi M. Kataoka T. Sakane H. Sezaki H. Tokuda 2000 Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells Eur. J. Pharm. Sci. 10 195 204
35. Y. Takahashi H. Kondo T. Yasuda T. Watanabe S. Kobayashi S. Yokohama 2002 Common solubilizers to estimate the Caco-2 transport of poorly water-soluble drugs Int. J. Pharm. 246 85 94
36. M. D. Levitt J. K. Furne A. Strocchi B. W. Anderson D. G. Levitt 1990 Physiological measurements of luminal stirring in the dog and human small bowel J. Clin. Invest. 86 1540 1547
37. M. D. Levitt T. Aufderheide C. A. Fetzer J. H. Bond D. G. Levitt 1984 Use of carbon monoxide to measure luminal stirring in the rat gut J. Clin. Invest. 74 2056 2064
38. D. Winne H. Gorig U. Muller 1987 Closed rat jejunal segment in situ: role of pre-epithelial diffusion resistance (unstirred layer) in the absorption process and model analysis Naunyn-Schmiedeberg's Arch. Pharmacol. 335 204 215
39. N. A. Kasim M. Whitehouse C. Ramachandran M. Bermejo H. Lennernas A. S. Hussain H. E. Junginger S. A. Stavchansky K. K. Midha V. P. Shah G. L. Amidon 2004 Molecular properties of WHO essential drugs and provisional biopharmaceutical classification Mol. Pharm. 1 85 96
40. W. L. Chiou S. Riegelman 1971 Absorption characteristics of solid dispersed and micronized griseofulvin in man J. Pharm. Sci. 60 1376 1380
41. A. L. Ungell S. Nylander S. Bergstrand A. Sjoberg H. Lennernas 1998 Membrane transport of drugs in different regions of the intestinal tract of the rat J. Pharm. Sci. 87 360 366
42. I. E. Borisevitch M. Tabak 1992 Electronic absorption and fluorescence spectroscopic studies of dipyridamole: effects of solution composition J. Lumin. 51 315 322
43. a values in a mixed-buffer linear pH gradient system Anal. Chem. 75 883 892
44. I. Legen A. Kristl 2003 pH and energy dependent transport of ketoprofen across rat jejunum in vitro Eur. J. Pharm. Biopharm. 56 87 94
45. a values of pharmaceuticals by pressure-assisted capillary electrophoresis and mass spectrometry Rapid Commun. Mass Spectrom. 17 2639 2648
46. W. N. Charman M. C. Rogge A. W. Boddy B. M. Berger 1993 Effect of food and a monoglyceride emulsion formulation on danazol bioavailability J. Clin. Pharmacol. 33 381 386
47. M. Valle E. Di Salle M. G. Jannuzzo I. Poggesi M. Rocchetti R. Spinelli D. Verotta 2005 A predictive model for exemestane pharmacokinetics/ pharmacodynamics incorporating the effect of food and formulation Br. J. Clin. Pharmacol. 59 355 364
48. S. Stiegler M. Birkel V. Jost R. Lange P. W. Lucker N. Wetzelsberger 1995 Pharmacokinetics and relative bioavailability after single dose administration of 25 mg ketoprofen solution as compared to tablets Methods Find. Exp. Clin. Pharmacol. 17 129 134
49. G. Mikus C. Fischer B. Heuer C. Langen M. Eichelbaum 1987 Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration Br. J. Clin. Pharmacol. 24 561 569
50. A. Melander G. Brante O. Johansson T. Lindberg E. Wahlin-Boll 1979 Influence of food on the absorption of phenytoin in man Eur. J. Clin. Pharmacol. 15 269 274
51. A. Karim J. Zagarella T. C. Hutsell A. Chao B. J. Baltes 1976 Spironolactone. II. Bioavailability Clin. Pharmacol. Ther. 19 170 176